Clinical Trials

Open label-Locally Advance/metastatic HR +/HER2 negative Breast cancer

Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-positive/​Human Epidermal Growth Factor Receptor 2 Negative (HR+/​HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) ID NCT05840211 

Protocol number GS-US-598-6168

Sponsor Gilead Sciences

Open label- Early Breast Cancer ER+/Her2 – Intermediate/high recurrence risk

A Study of Camizestrant in ER+/​HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) ID NCT05774951

Protocol number D8531C00002

Sponsor AstraZeneca


Observational- T-DXd (enhertu) 1st or 2nd line for HER2+, and HER2-low unresectable/metastatic breast cancer

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/​or Metastatic Breast Cancer (DB RESPOND) IDNCT05592483 

Protocol number D9673R00025

Sponsor AstraZeneca


Observational Solid tumor multi-cohort study

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE) ID NCT05059444

Protocol number 02-MX-003

Sponsor Guardant Health, Inc.


Stage I to II Non-small cell lung cancer

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients /​ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4) ID NCT03833154

Protocol number D9103C00001

Sponsor AstraZeneca


Locally Advanced (Stage III),Un-resectable non-small cell lung cancer

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) ID NCT05211895

Protocol number D9075C00001

Sponsor AstraZeneca


Previously untreated – First line Locally Advanced/metastatic non-small cell lung cancer

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) ID NCT05555732

Protocol number DS1062-A-U303

Sponsor Daiichi Sankyo


Open label Stage IIIB, IIIC, IV First line non-small cell lung cancer

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) ID NCT05215340

Protocol number DS1062-A-U304

Sponsor Daiichi Sankyo


Open label advanced or metastatic 2nd or 3rd line non-small cell lung cancer

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY) ID NCT05450692

Protocol number D533BC00001

Sponsor AstraZeneca


Newly diagnosed untreated LS-small cell lung cancer

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/​KEYLYNK-013) ID NCT04624204

Protocol number MK 7339-013

Sponsor Merck 


Open label relapsed small cell lung cancer

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) ID NCT05153239

Protocol number PM1183-C-008-21

Sponsor PharmaMar


Relapsed refractory diffused large B cell lymphoma

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/​Refractory Diffuse Large B-cell Lymphoma ID NCT04442022

Protocol number XPORT-DLBCL-030

Sponsor Karyopharm Therapeutics Inc


Metastatic castrate resistant prostate cancer

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts ID NCT02266745

Protocol number PT-112-101

Sponsor Promontory Therapeutics Inc.


Head and Neck Squamous Cell Carcinoma

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC) ID NCT04854499

Protocol number GS-US-548-5916

Sponsor Gilead Sciences


Relapsed or refractory Myelofibrosis

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/​Refractory Myelofibrosis (TRANSFORM-2) ID NCT04468984

Protocol number M20-178

Sponsor AbbVie



Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC ID NCT05199818

Protocol number LP-CT-PALO-202101

Sponsor Xiamen LP Pharmaceutical